進行性膵臓がんの治療のためのアルファ放射線エミッター装置
進行性膵臓癌に対する腫瘍内拡散アルファ線エミッターの実現可能性と安全性に関する研究
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.
調査の概要
状態
詳細な説明
This is a prospective, single-center, open label, single arm study. The study is designed to evaluate the feasibility, safety and preliminary efficacy of intratumoral alpha radiation mediated treatment with Alpha DaRT seeds for the treatment of advanced pancreatic cancer.
The study will be comprised of a screening period, DaRT insertion visit, acute follow-up phase of 4-6 weeks and a long-term follow up phase of 24 months. The total duration of the study will be 24 months from the DaRT insertion procedure.
30 patients with advanced pancreatic cancer will be recruited by the investigational site.
Eligible patients who meet inclusion/exclusion criteria (as assessed during the screening period) will be invited to the site for the procedure of DaRT seeds insertion. The patients will be monitored for a period of 24 months post insertion.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Quebec
-
Montreal、Quebec、カナダ
- Jewish General Hospital
-
Montreal、Quebec、カナダ
- Centre Hospitalier de l'Université de Montréal (CHUM)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically and/or cytologically proven locally advanced (Stage II or III) or metastatic (Stage IV) pancreatic, adenocarcinoma
- Inoperable pancreatic cancer due to at least one of the following: a) unresectability, b) metastatic disease, c) medically unfit for surgery
- ECOG performance status ≤ 2
- Measurable lesion per RECIST (version 1.1) criteria
- Maximum lesion of 4cm in the longest diameter (including primary tumor and regional lymph nodes)
- ≥ 18 years of age
- Estimated life expectancy of at least 12 weeks
- Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test
- Subjects are willing to sign an informed consent
Exclusion Criteria:
- Prior chemotherapy does not exclude the patient
- Prior abdominal radiation therapy
- Concomitant chemotherapy or immunotherapy
- Borderline resectable pancreatic cancer and medically fit for surgery
- Connective tissue disease (scleroderma, lupus)
- Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)
- Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids
- Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
- High probability of protocol non-compliance (in opinion of investigator)
- Patients not willing to sign an informed consent form
- Women who are pregnant or lactating
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:DaRT Seeds
Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds |
An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility - DaRT seed placement
時間枠:Day 0 (Day of insertion)
|
Assessment of the DaRT seed placement within the tumor or less than 5 mm from the tumor using CT imaging on the day of DaRT insertion. |
Day 0 (Day of insertion)
|
|
Safety - Adverse events
時間枠:3 months
|
Assessment of the frequency, severity and causality of acute AEs and SAEs related to DaRT seeds insertion. AEs and SAEs will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0 |
3 months
|
|
Safety - Adverse events
時間枠:3 to 24 months
|
Assessment of the frequency, severity and causality of Late AEs and SAEs related to DaRT seeds insertion. AEs and SAEs will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0. The follow up will be carried out by phone calls every 2 months during the time between 3 to 24 months after DaRT seeds insertion |
3 to 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficiency - Short-term effect
時間枠:4-6 weeks after DaRT seeds insertion
|
Assessment of the objective response rate (ORR) following DaRT seeds insertion using CT scan |
4-6 weeks after DaRT seeds insertion
|
|
Tissue damage evaluation
時間枠:Day -14 to 60 days after insertion
|
Measuring CA19-9 as a marker to tissue damage. Elevation during treatment, and reduction as a result of tumor ablation. Serum levels of CA 19-9 can be measured using chemiluminescent assay on an Unicel DxI 800 analyzer (BeckmanCoulter, Brea, CA, USA). |
Day -14 to 60 days after insertion
|
|
Efficiency - Long-term effect
時間枠:2 years following DaRT seeds insertion
|
Assessment of the overall survival (OS) following DaRT seeds insertion |
2 years following DaRT seeds insertion
|
|
Stent durability
時間枠:Day of DaRT insertion up to 24 months.
|
Stent durability will be assessed by the time elapsed from DaRT insertion to the need for follow-up referral for ERCP for stent change due to tumor ingrowth |
Day of DaRT insertion up to 24 months.
|
|
Change in quality of life: EORTC-QLQ-C30
時間枠:Day -14 to 60 days after insertion
|
Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires EORTC-QLQ-C30 (version 3.0). Scale range in score from 0 (best) to 100(worst). |
Day -14 to 60 days after insertion
|
|
Change in quality of life: QLQ-PAN26
時間枠:Day -14 to 60 days after insertion
|
Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires QLQ-PAN26. The module comprises 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). |
Day -14 to 60 days after insertion
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:David Donath, MD、Brachytherapy Service Centre Hospitalier de l'Université de Montreal
- 主任研究者:Corey Miller, MD、Division of Gastroenterology, Jewish General Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。